



Vivimed

Investor Release

Vivimed's FDF facility which obtained UKRAINE PICS approval in October 2017, obtains new product registrations and now signs Distribution Agreement

Hyderabad, India, February 12, 2018 – Vivimed Labs Limited ("Vivimed" or the Company), a niche Pharmaceuticals and Specialty Chemicals' company, announced today its unit 1 FDF manufacturing facility located in Hyderabad, post certification by Ukraine FDA, has successfully registered 8 products in anti viral, pain management and cough suppressants segment.

Vivimed has now inked a distribution agreement with 'Alter Ego LLC', Kieve, Ukraine which has more than a decade of presence in Ukraine, Russia and CIS regions. Vivimed is expecting revenues upwards of 10 million USD for FY19 from CIS region.

Commenting on the development, **Mr. Sandeep Varalwar, Executive Director** said:

"This agreement between Vivimed and Alter Ego is in line with company's vision of growth in CIS markets. The relationship will go a long way in establishing a robust growth in CIS markets and Vivimed will continue to add more new products to its range leveraging its strength in API manufacturing for new molecules.

About Vivimed Labs:

Vivimed is a Pharmaceuticals and Specialty Chemicals company head quartered in Hyderabad, India. It has manufacturing footprint across India, Europe and South America across its line of business and employs close to 2000 personnel across the world. Vivimed reported sales of about INR 15 bn for the financial year ended March 31, 2017.

For further information on Vivimed, visit www.vivimedlabs.com

*** **

For VIVIMED LABS LTD.

Company Secretary



Vivimed

Safe Harbour

This release contains “forward looking statements” including, but without limitation, statements relating to the implementation of strategic initiatives, and other statements relating to Vivimed’s future business developments and economic performance. While these forward looking statements indicate our assessment and future expectations concerning the development of our business, a number of risks, uncertainties and other unknown factors could cause actual developments and results to differ materially from our expectations. These factors include, but are not limited to, general market, macroeconomic, governmental and regulatory trends, movements in currency exchange and interest rates, competitive pressures, technological developments, changes in the financial conditions of third parties dealing with us, legislative developments, and other key factors that could affect our business and financial performance. Vivimed undertakes no obligation to publicly revise any forward looking statements to reflect future / likely events or circumstances.

For further information please contact	
<u>Company Contact:</u> Vivimed Labs Limited CIN No: L02411KA1988PLC009465 Sunil Arab Email: sunil.arab@vivimedlabs.com B. Rajaprasad Email: rajaprasad.B@vivimedlabs.com	<u>Investor Relations:</u> Strategic Growth Advisors Pvt Ltd. CIN No: U74140MH2010PTC204285 Rahul Agarwal Email: rahul.agarwal@sgapl.net Tel No: +91 79770 90416

For VIVIMED LABS LTD.


Company Secretary